S
Shanghai Wickhams Biomedical Technology
Committed to advancing in high-tech genetic testing
About Shanghai Wickhams Biomedical Technology
Shanghai Wickhams Biomedical Technology Co., Ltd., operating as WeHealth, is a high-tech genetic testing services company established in 2016. The company was co-founded by CEO Gaofei Peng, CTO Jingmin Yang, and COO Lingyun Tan. The founding team possesses a strong background in genetics and corporate management, with Dr. Yang, for instance, holding a Ph.D. in Human Medical Genetics from Fudan University, where he studied under the renowned academician Jin Li. This deep expertise in genetics is a core component of the company's foundation and ongoing research and development efforts. Located in the Shanghai International Medical Park, the company has positioned itself as a key player in the application of genetic testing technologies for hereditary diseases in China.
Wickhams Biomedical focuses on providing genetic testing services with a primary emphasis on reproductive health and the prevention and control of birth defects. Its business operations are segmented into several key areas, including genetic disease screening and diagnosis, testing for infertility and products of conception, and non-invasive prenatal testing for single-gene disorders (NIPT-M). The company serves a client base of hospitals and research institutions, collaborating with hundreds of top-tier medical organizations across the country. Revenue is generated through these specialized testing services and research collaborations. The company operates independent third-party medical laboratories in Shanghai and Chongqing, an IVD production base for test kits and equipment, and has established a comprehensive service network.
The service portfolio of Wickhams Biomedical is extensive, utilizing a range of testing platforms such as first and second-generation sequencing, and BioNano for detecting structural variations. Their offerings cover eugenics and genetic disease detection, including ophthalmic and dermatological genetic conditions, as well as providing scientific research services for institutional clients. The firm has achieved significant milestones, including receiving CAP certification, obtaining a medical institution practicing license, and being recognized as a National High-Tech Enterprise. The company has also secured multiple rounds of funding from notable investors like Matrix Partners China, HuaYao Capital, and Shengshan Asset Management, completing a Series B1 round in December 2023.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Huangpu, China
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2023 | $14M | $55M | Shanghai Qingrong Chuangzhi Group | ↗ |
| SERIES B✓Equity / VC | May 2021 | $14M | $55M | Horus Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Wickhams Biomedical Technology is 40 monthly website visits, down 71.4% over the last three months. Shanghai Wickhams Biomedical Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Wickhams Biomedical Technology in the Huangpu ecosystem
The Shanghai Wickhams Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Shengshan Asset Management
Series A2 investors entered at this stage
Horus Capital- SGShanghai Qingrong Chuangzhi Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Wickhams Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Wickhams Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









